Tagrisso data shows superiority over chemotherapy
06 December 2016 09:30 TAGRISSO DEMONSTRATES SUPERIORITY OVER CHEMOTHERAPY IN EGFR T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER First randomised Phase III trial (AURA3) of Tagrisso against chemotherapy Tagrisso reduced risk of disease progression by 70% and improved progression-free survival (PFS) by almost six months Patients with central nervous system metastases achieved similar benefit as the overall patient population in pre-specified exploratory subgroup analysis AstraZeneca today presented data from the AURA3 trial that is supportive of Tagrisso (osimertinib)